Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/20/2021 | $18.00 | Buy | Benchmark |
| 7/20/2021 | $18.00 | Buy | The Benchmark Company |
4 - Humacyte, Inc. (0001818382) (Issuer)
Benchmark initiated coverage of Alpha Healthcare with a rating of Buy and set a new price target of $18.00
The Benchmark Company initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $18.00
Lake Street initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $20.00
Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform
NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the
In addition to the Company's eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U
S-1 - Humacyte, Inc. (0001818382) (Filer)
8-K - Humacyte, Inc. (0001818382) (Filer)
8-K - Humacyte, Inc. (0001818382) (Filer)
SC 13G - Humacyte, Inc. (0001818382) (Subject)
SC 13D - Humacyte, Inc. (0001818382) (Subject)
SC 13D - Humacyte, Inc. (0001818382) (Subject)
Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform